- Home
- DNUT vs ZLAB Comparison
DNUT vs ZLAB Comparison
Compare DNUT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- ZLAB
- Stock Information
- Founded
- DNUT 1937
- ZLAB 2013
- Country
- DNUT United States
- ZLAB China
- Employees
- DNUT N/A
- ZLAB N/A
- Industry
- DNUT Food Chains
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- DNUT Consumer Staples
- ZLAB Health Care
- Exchange
- DNUT Nasdaq
- ZLAB Nasdaq
- Market Cap
- DNUT 505.6M
- ZLAB 3.6B
- IPO Year
- DNUT 2021
- ZLAB 2017
- Fundamental
- Price
- DNUT $3.35
- ZLAB $36.40
- Analyst Decision
- DNUT Buy
- ZLAB Buy
- Analyst Count
- DNUT 8
- ZLAB 5
- Target Price
- DNUT $10.23
- ZLAB $54.28
- AVG Volume (30 Days)
- DNUT 3.9M
- ZLAB 886.5K
- Earning Date
- DNUT 08-07-2025
- ZLAB 08-05-2025
- Dividend Yield
- DNUT 4.22%
- ZLAB N/A
- EPS Growth
- DNUT N/A
- ZLAB N/A
- EPS
- DNUT N/A
- ZLAB N/A
- Revenue
- DNUT $1,597,883,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- DNUT N/A
- ZLAB $44.07
- Revenue Next Year
- DNUT $2.80
- ZLAB $49.13
- P/E Ratio
- DNUT N/A
- ZLAB N/A
- Revenue Growth
- DNUT N/A
- ZLAB 43.72
- 52 Week Low
- DNUT $2.50
- ZLAB $16.01
- 52 Week High
- DNUT $12.68
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- DNUT 61.12
- ZLAB 52.67
- Support Level
- DNUT $2.50
- ZLAB $34.79
- Resistance Level
- DNUT $2.72
- ZLAB $36.73
- Average True Range (ATR)
- DNUT 0.18
- ZLAB 1.23
- MACD
- DNUT 0.12
- ZLAB -0.46
- Stochastic Oscillator
- DNUT 83.67
- ZLAB 25.91
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.